KR20170131543A - 근위축성 측삭 경화증을 치료하기 위한 비오틴 - Google Patents

근위축성 측삭 경화증을 치료하기 위한 비오틴 Download PDF

Info

Publication number
KR20170131543A
KR20170131543A KR1020177030427A KR20177030427A KR20170131543A KR 20170131543 A KR20170131543 A KR 20170131543A KR 1020177030427 A KR1020177030427 A KR 1020177030427A KR 20177030427 A KR20177030427 A KR 20177030427A KR 20170131543 A KR20170131543 A KR 20170131543A
Authority
KR
South Korea
Prior art keywords
biotin
treatment
patient
neuropathy
lateral sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177030427A
Other languages
English (en)
Korean (ko)
Inventor
프레데릭 세델
Original Assignee
메드데이 파마슈티컬스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170131543(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 메드데이 파마슈티컬스 filed Critical 메드데이 파마슈티컬스
Publication of KR20170131543A publication Critical patent/KR20170131543A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Magnetic Ceramics (AREA)
  • Manufacture, Treatment Of Glass Fibers (AREA)
KR1020177030427A 2015-03-26 2016-03-25 근위축성 측삭 경화증을 치료하기 위한 비오틴 Withdrawn KR20170131543A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305437.4A EP3072513A1 (en) 2015-03-26 2015-03-26 Biotin for treating Amyotrophic lateral sclerosis
EP15305437.4 2015-03-26
PCT/EP2016/056696 WO2016151132A1 (en) 2015-03-26 2016-03-25 Biotin for treating amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
KR20170131543A true KR20170131543A (ko) 2017-11-29

Family

ID=52779582

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177030427A Withdrawn KR20170131543A (ko) 2015-03-26 2016-03-25 근위축성 측삭 경화증을 치료하기 위한 비오틴

Country Status (24)

Country Link
US (2) US10357480B2 (https=)
EP (2) EP3072513A1 (https=)
JP (1) JP6752874B2 (https=)
KR (1) KR20170131543A (https=)
CN (2) CN107405335A (https=)
AU (1) AU2016238759B2 (https=)
BR (1) BR112017020408A2 (https=)
CA (1) CA2980660A1 (https=)
CY (1) CY1122374T1 (https=)
DK (1) DK3273957T3 (https=)
EA (1) EA034394B1 (https=)
ES (1) ES2748354T3 (https=)
HR (1) HRP20191491T1 (https=)
HU (1) HUE046116T2 (https=)
IL (1) IL254619B (https=)
LT (1) LT3273957T (https=)
MA (1) MA41809B1 (https=)
ME (1) ME03567B (https=)
PL (1) PL3273957T3 (https=)
PT (1) PT3273957T (https=)
RS (1) RS59149B1 (https=)
SI (1) SI3273957T1 (https=)
SM (1) SMT201900548T1 (https=)
WO (1) WO2016151132A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3275439A1 (en) 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
CN113164278B (zh) * 2018-12-11 2024-11-01 马优斯珀茨澳大利亚私人有限公司 粘合垫
CN112386703A (zh) * 2020-01-15 2021-02-23 李启芳 治疗als的联合用药物及其应用
US20240082296A1 (en) * 2020-10-09 2024-03-14 Tx Medic Ab Treatment of muscle atrophy using dextran sulfate
WO2023081458A1 (en) * 2021-11-08 2023-05-11 Rutgers, The State University Of New Jersey Systems and methods for diagnosis and/or treating demyelinating neuropathy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
UA86749C2 (en) 2002-09-27 2009-05-25 Байоджен Айдек Ма Инк. THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-в
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
WO2012145746A1 (en) * 2011-04-21 2012-10-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
KR101951220B1 (ko) * 2011-07-13 2019-02-22 싸이토키네틱스, 인코포레이티드 조합 als 치료법
CA2910717C (en) 2013-04-29 2021-01-26 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
JP6664956B2 (ja) * 2015-02-27 2020-03-13 キリンホールディングス株式会社 筋分化促進組成物
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
NZ735528A (en) 2021-09-24
AU2016238759A1 (en) 2017-10-05
JP6752874B2 (ja) 2020-09-09
US20190314342A1 (en) 2019-10-17
EP3072513A1 (en) 2016-09-28
CA2980660A1 (en) 2016-09-29
LT3273957T (lt) 2019-11-11
SMT201900548T1 (it) 2019-11-13
EP3273957A1 (en) 2018-01-31
EP3273957B1 (en) 2019-08-14
DK3273957T3 (da) 2019-11-11
US10357480B2 (en) 2019-07-23
IL254619B (en) 2020-03-31
WO2016151132A1 (en) 2016-09-29
CN107405335A (zh) 2017-11-28
SI3273957T1 (sl) 2019-11-29
PL3273957T3 (pl) 2020-01-31
EA034394B1 (ru) 2020-02-04
CY1122374T1 (el) 2021-01-27
ES2748354T3 (es) 2020-03-16
CN111973592A (zh) 2020-11-24
HRP20191491T1 (hr) 2019-11-15
IL254619A0 (en) 2017-11-30
HUE046116T2 (hu) 2020-02-28
JP2018512451A (ja) 2018-05-17
US20180125825A1 (en) 2018-05-10
BR112017020408A2 (pt) 2018-06-05
MA41809A (fr) 2018-01-30
EA201792124A1 (ru) 2018-04-30
RS59149B1 (sr) 2019-09-30
MA41809B1 (fr) 2019-12-31
AU2016238759B2 (en) 2020-08-06
PT3273957T (pt) 2019-09-18
ME03567B (me) 2020-07-20

Similar Documents

Publication Publication Date Title
JP6208235B2 (ja) 多発性硬化症治療のためのビオチンの使用
US20190314342A1 (en) Method for treating demyelinating neuropathy with biotin
JP5646617B2 (ja) 多発性硬化症の治療のための組成物および方法
US9789092B2 (en) Biotin for use in treating X-linked adrenoleukodystrophy
AU2015254661A9 (en) Treatment and prevention of Alzheimer's Disease (AD)
JP2020527156A (ja) 自己免疫性神経筋疾患を処置するためのクラドリビンの使用
NZ735528B2 (en) Biotin for treating demyelinating neuropathies
HK1243938A1 (en) Biotin for treating demyelinating neuropathies
HK1243938B (en) Biotin for treating demyelinating neuropathies
WO2024254701A1 (en) Ibogaine for the treatment of multiple sclerosis
EP2991645B1 (en) Biotin for use in treating x-linked adrenoleukodystrophy
CN112641765A (zh) 丙泊酚的抗疲劳制药用途
WO2011043788A2 (en) Daptomycin for multiple sclerosis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171023

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210324

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20220722

WITB Written withdrawal of application